Table 4. Univariate analysis of immune cell markers in tumour and stroma areas in HPV positive and negative patients.
| Markers | Patients | LRC (HR, 95% CI) | P value | OS (HR, 95% CI) | P value |
|---|---|---|---|---|---|
|
HPV+ve Tumour |
CD8+ CD8+PD-1+ CD68+ CD68+PD-L1+ PD-L1 |
1.56, 0.45–3.40 | 0.34 | 1.25, 0.60–2.61 | 0.55 |
| 0.90, 0.60–2.10 | 0.56 | 1.00, 0.50–1.89 | 0.34 | ||
| 0.90, 0.45–2.30 | 0.76 | 1.14, 0.37–3.44 | 0.81 | ||
| 0.70, 0.12–1.50 | 0.67 | 0.78, 0.67–2.34 | 0.56 | ||
| 0.45, 0.23–1.25 | 0.08 | 0.34, 0.10–1.07 | 0.06 | ||
|
HPV+ve Stroma |
CD8+ CD8+PD-1+ CD68+ CD68+PD-L1+ PD-L1 |
0.25, 0.12–1.05 | 0.05 | 0.37, 0.15–0.93 | 0.03 |
| 0.89, 0.67–1.40 | 0.15 | 0.35, 0.10–1.20 | 0.12 | ||
| 1.30, 0.50–3.20 | 0.23 | 4.0, 1.0 – 7.7 | 0.07 | ||
| 1.20, 0.34–2.30 | 0.56 | 1.30, 0.23–2.00 | 0.45 | ||
| 1.45, 0.60–3.40 | 0.76 | 1.62, 0.40–6.00 | 0.46 | ||
|
HPV–ve Tumour |
CD8+ CD8+PD-1+ CD68+ CD68+PD-L1+ PD-L1+ |
0.90, 0.20–3.40 | 0.78 | 0.56, 0.13–2.30 | 0.56 |
| 0.80, 0.34–5.60 | 0.59 | 0.45, 0.10–3.40 | 0.45 | ||
| 0.56, 0.23–1.70 | 0.56 | 0.94, 0.23–3.75 | 0.93 | ||
| 2.50, 0.90–3.40 | 0.08 | 3.10, 0.82–5.70 | 0.09 | ||
| 0.45, 0.12–0.78 | 0.78 | 0.38, 0.11–0.65 | 0.88 | ||
|
HPV–ve Stroma |
CD8+ CD8+PD-1+ CD68+ CD68+PD-L1+ PD-L1+ |
0.56, 0.12–3.60 | 0.67 | 0.67, 0.23–4.50 | 0.68 |
| 0.78, 0.34–2.70 | 0.78 | 0.45, 0.15–3.70 | 0.57 | ||
| 3.20, 0.95–5.70 | 0.05 | 4.00, 1.00–7.70 | 0.04 | ||
| 3.60, 1.50–4.70 | 0.03 | 4.00, 1.29–5.67 | 0.01 | ||
| 3.50, 1.80–6.70 | 0.04 | 4.60, 1.23–7.00 | 0.02 |